Combined Modality Therapy of Breast Carcinoma Phase III

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Outcome of African American women with breast cancer in cooperative group clinical trials

JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes 20 year results of a Southwest Oncology Group study

SE Rivkin;S Green;D Lew;JJ Costanzi;JW Athens;CK Osborne;CB Vaughn;S Martino Cancer 97(1):21-29

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 20-year results of a Southwest Oncology Group study

SE Rivkin;S Green;D Lew;H Glucksberg;N Gad-el-Mawla;J Costanzi;B Hoogstraten;J Athens;T Maloney;C Osborne;C Vaughn;S Martino Proc of the American Society of Clinical Oncology 18:69a(#259)

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study.

SE Rivkin;S Green;B Metch;H Glucksberg;N Gad-el-Mawla;JJ Constanzi;B Hoogstraten;J Athens;T Maloney;CK Osborne;CB Vaughn Classic Papers and Current Comments 1(1):85-93

Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: A pilot study.

KS Albain;S Green;M LeBlanc;S Rivkin;J O'Sullivan;CK Osborne Breast Cancer Research and Treatment 22:273-284

Prognostic significance of lymphocyte counts (LC) in primary breast cancer (PBC).

S Baumgaertel;R Livingston;S Rivkin;J O'Sullivan;S Green ASCO 11:83(#160)

Age < 35 years is an adverse prognostic feature in premenopausal node-positive breast cancer patients (PTS) in Southwest Oncology Group studies.

K Albain;S Green;S Rivkin;K Osborne ASCO 9:35(#132)

Adjuvant combination chemotherapy (CMFVP) vs L-phenylalanine mustard (LPAM) for operable breast cancer with positive axillary lymph nodes: 10 year results.

S Rivkin;S Green;CK Osborne;B Metch;H Glucksberg;R McDivitt;N Gad-el-Mawla;R Stephens;J Costanzi ASCO 8:24(#89)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women.

J Crowley;J Glick;J Godwin;CK Osborne The New England Journal of Medicine 319(26):1681-1692

Adjuvant chemotherapy for operable breast cancer with positiveaxillary nodes.

H Glucksberg;SE Rivkin;S Green;B Metch;CK Osborne;R McDivitt;R Stevens;J Costanzi ASCO 5:68(#265)

Adjuvant therapy of breast cancer: A Southwest Oncology Group experience

SE Rivkin;H Glucksberg;M Foulkes Recent Results Cancer Res 96:166-74

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes

S Rivkin;H Glucksberg;M Foulkes ASCO #C-488

Adjuvant therapy of breast cancer: The Southwest Oncology Group experience

WA Knight III;SE Rivkin;H Glucksberg;MA Foulkes;JJ Costanzi;RL Stephens;JW Athens;RM O'Bryan Breast Cancer Res & Treat 3(Suppl 1):27-33

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes

S Rivkin;H Glucksberg;M Foulkes ASCO #C-390

Combination chemotherapy (CMFVP) versus L-Phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: A Southwest Oncology Group study

H Glucksberg;SE Rivkin;S Rasmussen;B Tranum;N Gad-el-Mawla;J Costanzi;B Hoogstraten;J Athens;T Maloney;J McCracken;C Vaughn Cancer 50:423-434

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes

S Rivkin;H Glucksberg;M Foulkes ASCO #C-285

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: A comparison of CMFVP versus L-Pam (Southwest Oncology Group Study) In: Adjuvant Therapy of Cancer III

SE Jones;SE Salmon Grune and Stratton

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes

H Glucksberg;S Rivkin;S Rasmussen ASCO #C-367

Adjuvant chemotherapy for stage II breast cancer: A comparison of CMFVP versus L-PAM (Southwest Oncology Group study)

H Glucksberg;SE Rivkin;S Rasmussen Adjuvant Therapy of Cancer II , pp. 261-268

Adjuvant chemotherapy in stage II breast cancer

S Rivkin;H Glucksberg;S Rasmussen ASCO #C-255

Adjuvant chemotherapy in stage II breast cancer

H Glucksberg;S Rivkin International Conference on the Adjuvant Therapy of Cancer #53